Cervical cancer prevention is entering a new chapter in Algeria with the introduction of HPV vaccination into the national immunization program. But prevention is only half the story. For women diagnosed with invasive cervical cancer today, the treatment landscape is also changing — with advances in staging, radiotherapy, systemic therapy, immunotherapy, and coordinated multidisciplinary care reshaping how clinicians make decisions.
The updated Algerian National Therapeutic Guidelines in Medical Oncology capture this shift. Cervical cancer management is no longer defined by a single modality or by chemotherapy alone. Treatment now hinges on accurate staging, careful selection between surgery and definitive chemoradiation, optimal integration of brachytherapy, and — in advanced disease — biomarker-guided systemic therapy.
In Algeria, cervical cancer is the fourth most common cancer among women, with an average age at diagnosis of 62. National incidence sits at roughly 4.5 cases per 100,000 women — just above the WHO’s elimination threshold of 4.0 per 100,000 — while screening still relies on an opportunistic model rather than a fully organized, invitation-based program. It’s this combination — a disease just above the elimination line, and a treatment pathway that has genuinely modernized — that makes the current update worth close attention.
Staging Now Drives the Treatment Pathway
The first therapeutic decision hinges on the extent of disease. Modern imaging plays a growing role in defining local extension, lymph-node involvement, and distant spread, allowing treatment to be tailored to stage and to whether curative therapy is feasible.
Multidisciplinary assessment matters most when deciding whether localized disease is better managed with surgery or with definitive chemoradiation. Tumors that look similar on the surface can require very different strategies depending on size, parametrial involvement, nodal status, and other clinical factors.
Chemoradiation Remains the Curative Backbone for Locally Advanced Disease
For locally advanced cervical cancer, concurrent chemoradiation remains the standard of curative care. Weekly cisplatin given alongside external-beam radiotherapy continues to anchor treatment, followed by brachytherapy as an essential — not optional — final step.
Brachytherapy deserves particular emphasis here: it isn’t simply an additional radiation modality but a core part of curative treatment, delivering a highly conformal dose to the primary tumor while sparing surrounding organs. This means outcomes depend not just on access to systemic therapy, but on the availability and quality of specialized radiotherapy and brachytherapy services — a capacity question as much as a clinical one.
Cervical cancer is therefore a clear illustration of why oncology outcomes hinge on coordination across medical oncology, radiation oncology, gynecologic oncology, radiology, pathology, and supportive care.
Surgery Is Increasingly Reserved for Selected Cases
Surgery remains appropriate for carefully selected early-stage disease, with its extent guided by tumor characteristics, stage, fertility considerations, and the likelihood of achieving adequate oncologic control.
The goal isn’t to operate whenever a tumor is technically resectable — it’s to identify the approach most likely to provide durable disease control while minimizing unnecessary morbidity. For selected patients with early disease, fertility-preserving surgery may also be considered when oncologically appropriate, following careful multidisciplinary evaluation and individualized counseling.
Systemic Therapy Enters a New Era
The biggest shift in advanced and recurrent cervical cancer has been the arrival of immunotherapy in systemic treatment.
For patients with recurrent or metastatic disease, treatment choice increasingly depends not just on prior therapy and performance status, but on PD-L1 status, tested upfront on biopsy. In patients without prior cisplatin exposure, PD-L1-positive disease is treated with cisplatin plus paclitaxel and pembrolizumab, with bevacizumab added when tolerated; PD-L1-negative or unknown status still receives the platinum-taxane-bevacizumab backbone without the checkpoint inhibitor. The same PD-L1-stratified logic carries over for patients previously exposed to cisplatin, where carboplatin takes its place alongside paclitaxel, bevacizumab, and — if PD-L1 positive — pembrolizumab. In appropriately selected patients, immune checkpoint inhibition can now be added to systemic treatment — part of a broader move from one-size-fits-all chemotherapy toward biologically informed care.
The question clinicians now face isn’t simply which chemotherapy regimen to use, but which combination of systemic therapies best fits an individual patient’s biology and clinical picture.
Recurrent and Metastatic Disease Calls for Individualized Planning
Once cervical cancer recurs or spreads, treatment goals shift based on the pattern of recurrence, prior treatment, disease burden, performance status, and available options.
Systemic therapy remains central, while immunotherapy and anti-angiogenic approaches (such as bevacizumab) have widened the options for appropriately selected patients. Clinicians must also weigh prior chemoradiation exposure and the risk of cumulative toxicity. Beyond first-line treatment, there is no single standard — several cytotoxic agents (gemcitabine, docetaxel, 5-fluorouracil, vinorelbine, ifosfamide, irinotecan, paclitaxel, pemetrexed) offer modest activity — but pembrolizumab monotherapy is now an option in second line and beyond for PD-L1-positive patients who did not receive it earlier.
At this stage, multidisciplinary discussion is essential — particularly when weighing localized treatment of recurrence, re-irradiation, palliative radiotherapy, or systemic therapy.
Supportive Care Is Part of the Treatment Plan, Not an Afterthought
Cervical cancer’s impact extends well beyond tumor progression. Pain, bleeding, urinary and gastrointestinal complications, nutritional problems, sexual dysfunction, psychological distress, and treatment-related toxicity can all significantly affect quality of life. Clinicians are advised to stay particularly alert to genito-urinary or digestive fistulas associated with bevacizumab, notably in patients with a previously irradiated pelvis.
Modern care requires supportive and palliative services alongside anticancer treatment from the outset. Managing symptoms, preserving function, and addressing psychosocial and survivorship needs aren’t secondary — they’re core components of good oncology care.
From Prevention to a Continuum of Cancer Control
HPV vaccination gives Algeria a real opportunity to reduce the future burden of cervical cancer — but that impact will take years to materialize. The women diagnosed today still need timely diagnosis, accurate staging, access to curative radiotherapy and brachytherapy, appropriate systemic treatment, and multidisciplinary follow-up.
Together, this forms a continuum: preventing HPV infection, catching disease earlier, treating invasive cancer effectively, and supporting survivorship.
Clinical Perspective
Algeria’s evolving cervical cancer care reflects a broader shift in oncology. Prevention matters more than ever, but so does modernizing treatment for the women who already have invasive disease. Contemporary care combines accurate staging, selective surgery, definitive chemoradiation and brachytherapy, and increasingly biomarker-informed systemic therapy into one coordinated pathway.
The most important progress here isn’t a single new drug or device — it’s the shift toward a more complete model of care, where prevention, diagnosis, radiotherapy, systemic treatment, multidisciplinary decision-making, and survivorship function as one continuum rather than separate silos.
As Algeria enters a new era of cervical cancer prevention, strengthening the treatment pathway for women already affected by the disease is equally essential. The goal isn’t only to prevent future cases — it’s to ensure every woman diagnosed today gets timely, evidence-based, increasingly personalized care.